A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited treatment options.

Panelists discuss how biomarker development in anal cancer remains limited with PD-L1 status not influencing treatment ...

• Key Intrahepatic cholangiocarcinoma pipeline therapies in various stages of development include Zanidatamab, Derazantinib, MIV-818, Bemarituzumab, KIN-3248, TYRA-200, Nelitolimod, and others.

Recent developments in the biliary tumor drug landscape have substantially expanded treatment options. In May 2024, AstraZeneca initiated Phase III clinical trials for Rilvegostomig, a promising ...

From new payload linkers to artificial intelligence partnerships, advances in ADC pipelines push forward selective cancer therapies that minimize side effects.

Immutep is continuing the AIPAC-003 trial, which enrolled 71 metastatic hormone receptor positive (HR+), HER2-negative/low or ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose ...

SUZHOU, China, July 29, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation ...

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...

DelveInsight's Claudin 18.2 Directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report ...